Prothionamide is a second-line anti-TB drug of the thioamide group, structurally related to ethionamide. It is used in MDR-TB regimens, especially in Asia.
Also known as: Protothionamide
Antituberculous + CYP inhibitor: fluconazole may increase protionamide levels.
Protionamide is metabolised by CYP enzymes. Fluconazole inhibits CYP, increasing levels and hepatotoxicity risk.
AST, ALT, bilirubin.
Severe hepatitis.
Monitor transaminases monthly.
DailyMed/FDA; EMC-EMC PT
No documented food or drink interactions.
No documented disease interactions.
No documented pregnancy or breastfeeding information.
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Prothionamide is a prodrug structurally related to ethionamide, activated by the same LiuA enzyme, with an identical mechanism of action (inhibition of mycolic acid synthesis).
Activated by LiuA to the active sulfoxide — same mechanism as ethionamide (inhibition of mycolic acid synthesis).
Oral bioavailability: nearly complete. Tmax: 2-3 hours. Absorption improved with food.
Hepatically metabolised. Metabolic profile similar to ethionamide.
2-3 hours. Elimination: urine (metabolites).
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
